mTOR、LC3蛋白表达与Ⅰ期非小细胞肺癌相关性的研究

Long term survival of mTOR and LC3 protein expression in stage Ⅰ small cell lung cancer

目的检测mTOR和LC3在Ⅰ期非小细胞肺癌组织中的表达量,探究二者与患者长期生存率的关系。方法将组织标本分为Ⅰ期非小细胞肺癌组和癌旁组织对照组,分别应用免疫组化法检测检测mTOR和LC3在两组组织中的表达量,分析比较5年存活率与mTOR和LC3蛋白表达量的关系。结果肺癌组中mTOR蛋白表达量显著高于癌旁组织对照组,差异具有统计学意义(=23.94,P<0.05)。肺癌组中LC3蛋白表达量明显低于癌旁组织对照组,差异具有统计学意义(=17.76,P<0.05)。Ⅰ期非小细胞肺癌患者中mTOR蛋白阳性者5年存活率为45.16%(14/31),mTOR蛋白阴性者5年存活率为92.86%(13/14),mTOR蛋白阴性者5年存活率高于阳性者,二者差异有统计学意义(P<0.05)。Ⅰ期非小细胞肺癌患者中LC3蛋白阳性者5年存活率为66.67%(26/39),LC3蛋白阴性者5年存活率为16.67%(1/6),LC33蛋白阳性者五年存活率高于阴性者,但二者差异没有统计学意义(P>0.05)。结论 mTOR在Ⅰ期非小细胞肺癌中表达上调LC3表达下调,而LC3蛋白阳性者mTOR蛋白可能是Ⅰ期非小细胞肺癌预后的危险因素。

Objective To detect the expression of mTOR and LC3 in stage Ⅰ non-small cell lung cancer（NSCLC）,and to explore the relationship between the two factors and long-term survival rate.Methods The tissue samples were divided into stage Ⅰ non-small cell lung cancer group and paracancerous tissue control group.The expressions of mTOR and LC3 in two groups were detected by immunohistochemistry,and the relationship between the 5 year survival rate and the expression of mTOR and LC3 protein was analyzed and compared.Results mTOR protein positive rate in the first stage of non small cell lung cancer tissues were 68.39%（31/45）,the positive rate in tumor tissues was 17.78%（8/45）,was significantly higher than that in the adjacent tissues of control group the expression of mTOR protein in lung cancer group,and the difference was statistically significant（=23.94,P〈0.05）.LC3 protein positive rate of non small cell lung cancer tissues were 44.44%（20/45）,the positive rate in tumor tissues was 86.67%（39/45）,was significantly lower than that of the adjacent tissues of control group the expression of LC3 protein in lung cancer group,the difference was statistically significant（=17.76,P〈0.05）.Patients with stage Ⅰ non-small cell lung cancer,the five year survival rate of mTOR protein positive was 45.16%（14/31）.The five year survival rate of patients with mTOR protein negative was 92.86%（13/14）.The five year survival rate of mTOR negative patients was higher than that of the positive ones,and the difference between the two groups was statistically significant（P〈0.05）.In patients with stage I non-small cell lung cancer,the five year survival rate of LC3 protein positive was 66.67%（26/39）.The five year survival rate of patients with LC3 protein negative was 16,67%（1/6）,and the five year survival rate of LC33 protein positive patients was higher than that of negative ones,but the difference between the two groups was not statistically significant（P〉0.05）.Conclusion The expression of mTOR is up-regulated and the expression of LC3 is down regulated in stage I non-small cell lung cancer.The mTOR protein in LC3 positive patients may be a risk factor for the prognosis of stage I non-small cell lung cancer,and LC3 protein may be a protective factor.